A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumours

Official Title

A Multicentre, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumours

Summary:

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumours.

Trial Description

Primary Outcome:

  • Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181
  • Time to Cmax (Tmax) of ABBV-927
  • Maximum observed serum concentration (Cmax) of ABBV-927
  • Terminal half-life (t1/2) of ABBV-927
  • Area under the serum concentration-time curve (AUC) of ABBV-927
  • Time to Cmax (Tmax) of ABBV-181
  • Maximum observed serum concentration (Cmax) of ABBV-181
  • Terminal half-life (t1/2) of ABBV-181
  • Area under the serum concentration-time curve (AUC) of ABBV-181
Secondary Outcome:
  • Clinical benefit rate (CBR, defined as the percentage of participants with a confirmed partial, complete response, or stable disease for at least 24 weeks to the treatment)
  • Duration of objective response (DOR)
  • Objective response rate (ORR)
  • Progression-free survival (PFS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society